0000000000018278

AUTHOR

Mahesh M K Parmar

showing 1 related works from this author

Exploratory outcome analyses according to stage and residual disease in the ICON7 trial of front-line carboplatin/paclitaxel (CP) ± bevacizumab (BEV)…

2015

5548 Background: In ICON7, progression-free survival (PFS) was significantly improved in patients (pts) receiving BEV with front-line CP and continued as a single agent [Perren 2011] but no overall...

OncologyCancer Researchmedicine.medical_specialtyBevacizumabbusiness.industrydigestive oral and skin physiologyFront lineDiseasemedicine.diseaseCarboplatin/paclitaxelSurgeryOncologyInternal medicineMedicineSingle agentIn patientStage (cooking)businessOvarian cancermedicine.drugJournal of Clinical Oncology
researchProduct